Search by property

This page provides a simple browsing interface for finding entities described by a property and a named value. Other available search interfaces include the page property search, and the ask query builder.

List of results

• Akiba et al. (2018): Vitamin D Supplementation and Survival of Patients with Non–small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial  + (T0: Baseline)
• Tan et al. (2018): Bromelain has significant clinical benefits after extraction of the third molar during chemotherapy in patients with hematologic tumor  + (T0: Baseline T1: 1 day after surgery T2: 3 days after surgery T3: 7 days after surgery (+quality of life))
• Muecke et al. (2010): Multicenter, phase 3 trial comparing selenium supplementation with observation in gynecologic radiation oncology  + (T0: Baseline T1: Half of the radiotherapy (about 4 weeks) T2: End of radiotherapy T3: 6 weeks after radiotherapy)
• Mansouri et al. (2016): The Effect of Aloe Vera Solution on Chemotherapy-Induced Stomatitis in Clients with Lymphoma and Leukemia: A Randomized Controlled Clinical Trial  + (T0: Baseline T1: day 1 T2: day 3 T3: day 5 T4: day 7 T5: day 14)
• Dale et al. (2001): Co-medication with hydrolytic enzymes in radiation therapy of uterine cervix: evidence of the reduction of acute side effects  + (T0: Baseline T1: weekly for 5 weeks Follow-up: after 6 weeks and 5 month after intervention)
• Johansson et al. (2021): Vitamin D Supplementation and Disease-Free Survival in Stage II Melanoma: A Randomized Placebo Controlled Trial  + (T0: Baseline 13 follow-up visits (4th, 8th, 12th, 16th, 20th, 24th, 28th, 32nd, 36th, 42nd, 48th, 54th, and 60th month))
• Jacot et al. (2016): Impact of a tailored oral vitamin D supplementation regimen on serum 25-hydroxyvitamin D levels in early breast cancer patients: a randomized phase III study  + (T0: Baseline At 6, 12, 18 and 24 months)
• Van Zandwijk et al. (2000): EUROSCAN, a Randomized Trial of Vitamin A and N-Acetylcysteine in Patients With Head and Neck Cancer or Lung Cancer  + (T0: Baseline Follop-up: at least 2 years after randomization)
• Toma et al. (2003): β-carotene supplementation in patients radically treated for stage I-II head and neck cancer: Results of a randomized trial  + (T0: Baseline Follow-up, median (range) per arm: - intervention: 61 (1-116) month - control: 58 (1-123) month)
• Meyskens et al. (1995): Effects of vitamin A on survival in patients with chronic myelogenous leukemia: a SWOG randomized trial  + (T0: Baseline Follow-up, median (range): 76 (37-111) months)
• Attia et al. (2008): Randomized, Double-Blinded Phase II Evaluation of Docetaxel with or without Doxercalciferol in Patients with Metastatic, Androgen-Independent Prostate Cancer  + (T0: Baseline On day 1 of every 28-day cycle)
• Argyriou et al. (2006): A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results  + (T0: Baseline T1 or T2: after 3rd or 6th chemotherapy cycle T3: 3 months post-chemotherapy)
• Argyriou et al. (2006): Preventing Paclitaxel-Induced Peripheral neuropathy: A Phase 2 Trial of Vitamin E Supplementation  + (T0: Baseline T1 or T2: after 3rd or 6th chemotherapy cycle T3: 3 months post-chemotherapy)
• Frankling et al. (2021): ‘Palliative-D’ - Vitamin D Supplementation to Palliative Cancer Patients: A Double Blind, Randomized Placebo-Controlled Multicenter Trial  + (T0: Baseline T1-T3: every worth week)
• Emami et al. (2014): Double-blinded, randomized, placebo-controlled study to evaluate the effectiveness of green tea in preventing acute gastrointestinal complications due to radiotherapy  + (T0: Baseline T1: * Diarrhea and vomiting … T0: Baseline</br>T1: </br>* Diarrhea and vomiting scaling weekly for 4 weeks (2nd-5th) </br>* daily diary (number, consistency of stools, occurrence of symptoms such as nausea, vomiting and gastrointestinal cramps) from day 1 of the 2nd week to the end of the 5th weekof the 2nd week to the end of the 5th week)
• Henning et al. (2015): Randomized Clinical Trial of Brewed Green and Black Tea in Men With Prostate Cancer Prior to Prostatectomy  + (T0: Baseline T1: Green tea arm: after an average of 33 days Black tea arm: after an average of 31 days Water arm: after an average of 29 days)
• Villani et al. (2016): Vitamin E neuroprotection against cisplatin ototoxicity: Preliminary results from a randomized, placebo-controlled trial  + (T0: Baseline T1: 1 month T2: 2 month T3: 3 month)
• Hershman et al. (2018): Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L Carnitine  + (T0: Baseline T1: 12th week T2: 24th week T3: 36th week T4: 52nd week T5: 104th week)
• Ehrenpreis et al. (2005): A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Retinol Palmitate (Vitamin A) for Symptomatic Chronic Radiation Proctopathy  + (T0: Baseline T1: 30 Tage T2: 60 tage T3: 90 Tage)
• Khodabakhshi et al. (2019): Feasibility, Safety, and Beneficial Effects of MCT-Based Ketogenic Diet for Breast Cancer Treatment: A Randomized Controlled Trial Study  + (T0: Baseline T1: 3rd visit (after about 9 weeks) T2: after 3 months)
• Mantovani et al. (2010): Randomized Phase III Clinical Trial of Five Different Arms of Treatment in 332 Patients with Cancer Cachexia  + (T0: Baseline T1: 4 weeks T2: 8 weeks T3: 16 weeks)
• Li et al. (2018): Efficacy of Ginger in Ameliorating Acute and Delayed Chemotherapy-Induced Nausea and Vomiting Among Patients With Lung Cancer Receiving Cisplatin-Based Regimens: A Randomized Controlled Trial  + (T0: Baseline T1: Acute symptoms 2 days after chemotherapy T2: 5 days after chemotherapy)
• Zick et al. (2008): Phase II trial of encapsulated ginger as a treatment for chemotherapy-induced nausea and vomiting  + (T0: Baseline T1: After 1 hour of completion of chemotherapy T2: 3 days after the end of their chemotherapy treatment)
• Rastelli et al. (2011): Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial  + (T0: Baseline T1: At 2 months T2: At 4 months T3: At 6 months)
• Uthaipaisanwong et al. (2020): Effects of ginger adjunct to the standard prophylaxis on reducing carboplatin and paclitaxel-induced nausea vomiting: a randomized controlled study  + (T0: Baseline T1: Day 1 of chemotherapy T2: Day 2-5 of chemotherapy)

• Asfour et al. (2006): Effect of high-dose sodium selenite therapy on polymorphonuclear leukocyte apoptosis in non-Hodgkin's lymphoma patients  + (T0: Baseline T1: Day 3 T2: Day 8)

• Margalit et al. (2012): Beta-carotene Antioxidant Use During Radiation Therapy and Prostate Cancer Outcome in the Physicians’ Health Study  + (T0: Baseline T1: Follow-up, median (range): 10.5 years (0.3-27.2))
• Mayne et al. (2001): Randomized Trial of Supplemental beta-Carotene to Prevent Second Head and Neck Cancer  + (T0: Baseline T1: Follow-up, median (range): 51.1 (30-90) months)
• Wrbka et al. (1987): Unterstützung der Chemotherapie inoperabler Karzinome durch proteolytische Fermente  + (T0: Baseline T1: On average 2 weeks (1-4 weeks))
• Cohen et al. (2018): Favorable Effects of a Ketogenic Diet on Physical Function, Perceived Energy, and Food Cravings in Women with Ovarian or Endometrial Cancer: A Randomized, Controlled Trial  + (T0: Baseline T1: after 12 weeks)
• Chan et al. (2011): Nutritional supplements, COX-2 and IGF-1 expression in men on active surveillance for prostate cancer  + (T0: Baseline T1: after 12 weeks)
• Stauder et al. (1991): Strahlentherapeutische Nebenwirkungen bei Abdominalkrebspatienten und deren Reduktion durch hydrolytische Enzyme  + (T0: Baseline T1: after 2 weeks T2: after 5 weeks)
• Kessels et al. (2017): Topical Sinecatechins, 10%, Ointment for Superficial Basal Cell Carcinoma A Randomized Clinical Trial  + (T0: Baseline T1: after 3 weeks T2: after 6 weeks T3: after 8 weeks (directly before operation))
• Pace et al. (2010): Vitamin E neuroprotection for cisplatin neuropathy  + (T0: Baseline T1: after 3. chemotherapy cycle T2: 1 month post-chemotherapy)
• Cruciani et al. (2012): L-Carnitine Supplementation for the Management of Fatigue in Patients With Cancer: An Eastern Cooperative Oncology Group Phase III, Randomized, Double-Blind, Placebo-Controlled Trial  + (T0: Baseline T1: after 4 weeks (first phase) T2: after 8 weeks (second phase))
• Stendell-Hollis et al. (2010): Green tea improves metabolic biomarkers, not weight or body composition: a pilot study in overweight breast cancer survivors  + (T0: Baseline T1: after 6 month)
• Zalat et al. (2020): Evaluation of the cardioprotective effects of l-carnitine and silymarin in cancer patients receiving anthracycline-containing chemotherapy  + (T0: Baseline T1: after 6 months of chemotherapy)
• Lian et al. (2014): Comparing the Effectiveness of Green Tea versus Topical Metronidazole Powder in Malodorous Control of Fungating Malignant Wounds in a Controlled Randomised Study  + (T0: Baseline T1: after 7 days)
• Nguyen et al. (2012): Randomized, Double-Blind, Placebo-Controlled Trial of Polyphenon E in Prostate Cancer Patients before Prostatectomy: Evaluation of Potential Chemopreventive Activities  + (T0: Baseline T1: after an average of 3 to 6 weeks until the operation)
• Dörr et al. (2007): Efficacy of Wobe-Mugos E for Reduction of Oral Mucositis after Radiotherapy  + (T0: Baseline T1: after at least 6 weeks)
• Azizi et al. (2015): Efficacy of Topical and Systemic Vitamin E in Preventing Chemotherapy-induced Oral Mucositis  + (T0: Baseline T1: after first cycle T2: after second cycle T3: after third cycle T4: after fourth cycle)
• Jyothirmayi et al. (1996): Efficacy of Vitamin A in the Prevention of Locoregional Recurrence and Second Primaries in Head and Neck Cancer  + (T0: Baseline T1: after three years)
• Najafizade et al. (2013): Preventive effects of zinc sulfate on taste alterations in patients under irradiation for head and neck cancers: A randomized placebo-controlled trial  + (T0: Baseline T1: at the end of radiotherapy Follow-Up: a month later)
• Khan et al. (2017): Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial  + (T0: Baseline T1: at week 12 T2: at week 24)
• Gujral et al. (2001): Efficacy of hydrolytic enzymes in preventing radiation therapy-induced side effects in patients with head and neck cancers  + (T0: Baseline T1: weekly for 8 weeks during radiation Follow up 1: 6-8 weeks after end of radiation Follow-up 2: 2-3 month after end of radiation Follow-up 3: 5-6 month after end of radiation)
• Lissoni et al. (2009): A Randomized Study of Chemotherapy versus Biochemotherapy with Chemotherapy plus Aloe arborescens in Patients with Metastatic Cancer  + (T0: Baseline T1: weekly until progression of diasease Follow-up: after 3 years)
• Marucci et al. (2017): Double-blind randomized phase III study comparing a mixture of natural agents versus placebo in the prevention of acute mucositis during chemoradiotherapy for head and neck cancer  + (T0: Baseline T1: weekly visits for 6 weeks)
• Mix et al. (2015): Randomized phase II trial of selenomethionine as a modulator of efficacy and toxicity of chemoradiation in squamous cell carcinoma of the head and neck  + (T0: Baseline T1: Week 4 T2: Week 7 during treatment T3: Week 6-8 post-treatment T4: Follow-up 3 months after completion of the study and then at further 3-month intervals over 2 years, then every 6 months until 5 years thereafter)
• Mansourian et al. (2015): The effect of "curcuma Longa" topical gel on radiation -induced oral mucositis in patients with head and neck cancer  + (T0: Baseline T1-T3: Tag 7, 14, 21)
• Dos Santos Martins (2016): Placebo-Controlled, Double-Blind, Randomized Study of a Dry Guarana Extract in Patients with Head and Neck Tumors Undergoing Chemoradiotherapy: Effects on Fatigue and Quality of Life  + (T0: Baseline T1: After 3 weeks T2: After 6 weeks T3: After 9 weeks)
• Shooriabi et al. (2016): The effect of ginger extract on radiotherapy-oriented salivation in patients with xerostomia: A double-blind controlled study  + (T0: Baseline T1: End of study)